Clinical Trials

The ADVICE trial is an active trial that is recruiting patients in Australia.

The trial is open to patients with any form of solid (non-blood) cancer encompassing both carcinomas and sarcomas. The trial will enroll up to about 80 patients.

The trial is designed to evaluate the safety and anti-cancer activity of KESONOTIDE™ as a monotherapy in patients with cancers that are progressing on standard of care.

The rationale involves a novel mechanism of action designed to break the partnership of two key proteins – EGFR and vimentin – in driving cancer aggression, invasiveness, spread and recurrence.

For further information please contact: clinicaltrials@filamon.com

Click here to see the KESONOTIDE cancer clinical trial >> ClinicalTrials.gov